Collection of biological samples for rare pediatric autoimmune and autoinflammatory diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on creating a biological collection of samples from patients with rare pediatric-onset autoimmune and autoinflammatory diseases, such as systemic lupus and juvenile dermatomyositis. It aims to gather primary cells, DNA, RNA, lymphoblastic lines, and serum to facilitate research into the genetic and immunological abnormalities associated with these conditions. By addressing the challenges posed by the rarity of these diseases and the limited availability of biological samples, the study seeks to enhance understanding and diagnosis of these severe conditions that often begin in childhood.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients
* minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (\<18 years), or syndromic or familial
* relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (\<18 years of age) or syndromic or familial,
* weight greater than 5 kg
* Patient/parents/guardians who were informed of the study and signed the consent form.
* patient affiliated to a social security scheme

Healthy volunteer participants

* minor or adult participants with no age restrictions
* weight over 5 kg
* Subject /Parents/guardians who were informed of the study and signed a consent form.
* Patient affiliated to a social security scheme

Exclusion Criteria:

Patients

\- Subjects /Parents/guardians, refusing to participate in the study

Healthy volunteer participants :

* active infection (viral, bacterial, parasitic)
* history of neoplasia (\< 5 years) or current neoplasia
* participants with a personal or family history of autoimmune disease
* immunocompromised participant (immune deficiency or transplant recipient)
* Subjects/parents/guardians refusing to participate in the study
* Adults under legal protection (guardianship, curatorship)

Where it's running

• Service de rhumatologie pédiatrique Hôpital Femme-Mère-enfant
  Bron, Bron, France Recruiting
• Dr Isabelle MELKI
  Paris, France Recruiting
• Pr Ariane ZALOSZYC
  Strasbourg, France Recruiting
• Dr Vanessa Remy-Piccolo
  Villefranche-sur-Saône, France Recruiting
• Hôpital Jeanne de Flandre (CHU de Lille)
  Lille, Lille, France Not yet recruiting
• Hôpital Claude Huriez (CHU de Lille)
  Lille, Lille, France Not yet recruiting

Study contacts

• Study coordinator: BELOT Alexandre, Pr
• Email: Alexandre.belot@chu-lyon.fr
• Phone: + 33 4 27 85 61 26

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Natural history of type I interferonopathies in a European patient group

  This project will follow people with genetically confirmed type I interferonopathies across European centers to see how the disease develops and which clinical and blood markers track disease activity.

  Recruiting at 18 sites Imagine Institute · Innsbruck and 31 other locations · NCT07040774

• Profiling blood biomarkers in patients with systemic inflammatory diseases

  This study is testing how different blood markers change over time in people with systemic inflammatory diseases to improve diagnosis and treatment options.

  Recruiting at 4 sites University Hospital, Ghent · Antwerp and 6 other locations · NCT05670301

• Identifying biomarkers in autoimmune and inflammatory diseases

  This study is trying to find specific markers in the blood of people with autoimmune diseases to help tailor their treatment and track how well it works.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, France · NCT05383339

• Gene editing and iPS cells to study and treat monogenic autoinflammatory diseases

  Researchers are testing whether correcting disease-causing mutations in patient-derived cells can help treat autoinflammatory conditions like SAVI and COPA using gene editing and iPSC technology.

  Recruiting at 2 sites Istituto Giannina Gaslini · Bari and 1 other locations · NCT07889947

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.